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Molecular construction of HIV-gp120
discontinuous epitope mimics by assembly
of cyclic peptides on an orthogonal alkyne
functionalized TAC-scaﬀold†
P. R. Werkhoven,a M. Elwakiel,a T. J. Meuleman,a H. C. Quarles van Uﬀord,a
J. A. W. Kruijtzera and R. M. J. Liskamp*a,b
Mimics of discontinuous epitopes of for example bacterial or viral proteins may have considerable poten-
tial for the development of synthetic vaccines, especially if conserved epitopes can be mimicked.
However, due to the structural complexity and size of discontinuous epitopes molecular construction of
these mimics remains challeging. We present here a convergent route for the assembly of discontinuous
epitope mimics by successive azide alkyne cycloaddition on an orthogonal alkyne functionalized scaﬀold.
Here the synthesis of mimics of the HIV gp120 discontinuous epitope that interacts with the CD4 receptor
is described. The resulting protein mimics are capable of inhibition of the gp120–CD4 interaction. The
route is convergent, robust and should be applicable to other discontinuous epitopes.
Introduction
There is great therapeutic potential for protein surface mimics
of bacterial and viral proteins involved in infectious diseases.
These protein mimics may be capable of inhibition or even
prevention of the binding of these proteins to their cellular
targets and are important for the design of synthetic vaccines.
As part of a program to address the synthetic challenges for
the construction of protein mimics encompassing diﬀerent
peptide segments, we have been involved in (1) the develop-
ment of syntheses of diﬀerent scaﬀolds for the attachment of
(cyclic) peptides,1 (2) synthetic approaches for the attachment
of diﬀerent (cyclic) peptides to these scaﬀolds2 and (3) the
generation of libraries of the resulting protein mimics.3
The practicality and eﬃciency of the synthesis of protein
mimics, with respect to yield, purity and possibilities for
expansion to collections or libraries, is an increasingly
important issue in the preparation of these relatively complex
biomolecular constructs of “intermediate size”.4 Convergent
methods for introducing both diﬀerent and several peptide
loops onto suitable scaﬀolds would greatly contribute to this.
Synthesis of especially discontinuous epitope mimics
remains very challenging because of their structural complex-
ity. A continuous epitope, which consists of a single contigu-
ous row of amino acids (Fig. 1 left), can be relatively easily
mimicked by one corresponding single linear or cyclic peptide.
In contrast to this, mimicry of a discontinuous epitope, which
consists of multiple peptide segments of the protein that
are far apart in the primary sequence but are brought together
by the folding of the protein (Fig. 1 right), is far more
challenging.
Our strategy for the mimicry of discontinuous epitopes is
scaﬀolding (Fig. 2). In this approach peptides corresponding
to the amino acid sequence of the epitope are synthesized and
attached to a small molecular scaﬀold. This scaﬀold should
provide the pre-organization of the peptides that is required to
accurately mimic an epitope. Many current synthetic routes for
Fig. 1 Structural classes of protein–protein interaction sites: continu-
ous (left) and discontinuous (right).
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a scaﬀolded protein mimic are often lengthy and not very
eﬃcient.2a,b,5 Furthermore, most synthetic routes are develo-
ped for incorporation of linear peptides or do not allow for the
introduction of diﬀerent peptides.2b,3a,b,6 It is believed that
cyclic peptides provide better mimics of the shape of the
epitope as it is in the protein context. An additional, albeit
very important reason for incorporation of cyclic peptides is
the possible increased proteolytic stability, which from a thera-
peutic applications perspective is a determining factor.
Recently, we described a convergent synthesis of protein
mimics by sequential native chemical ligation.2d Here, we
describe a more robust convergent synthetic route for the
assembly of three cyclized peptides to an orthogonal alkyne
functionalized scaﬀold. The versatile preparation of the
scaﬀold and the convenient accessibility of the cyclic peptides
are clear indicators of this robustness. Our synthesis strategy
is illustrated by the synthesis of protein mimics of the viral
envelope HIV gp120 protein encompassing its binding site
with CD4 cellular receptor (Fig. 2). The resulting mimics
are able to compete with gp120 for binding to CD4 in an
ELISA assay.
In contrast to our earlier work,8 we have streamlined the
synthesis of the required scaﬀold. In addition, the sequential
ligation procedure has been improved by combining the cyclo-
addition and deprotection reactions in a single pot. Finally, it
is shown that the synthesized mimics are capable of behaving
as a protein mimic of HIV gp120 interacting with the CD4
receptor.
Results and discussion
Scaﬀold synthesis
Introduction of the (protected) alkynes moieties was achieved
using (protected) pentynoic acid derivatives. The choice of the
triethylsilyl (TES) and triisopropylsilyl (TIPS) groups was orig-
inally based on the work of Valverde et al.9 Our previous
results have shown that this strategy worked excellently.8 The
synthesis of protected pentynoic acid derivatives is shown in
Scheme 1. First, the carboxylic acid functionality of pentyonic
acid (1) was protected as a tert-butyl ester (2). Next, the silyl-
protecting groups were introduced using n-BuLi and triethyl-
silyl chloride or triisopropylsilyl chloride. Both protected
alkynes (3a & 3b) were obtained in good yields (ca. 70%). By
treatment with TFA the tBu ester was hydrolysed to aﬀord the
final silyl protected pentynoic acid derivatives (4a and 4b).
From the modest yield of the TES-protected derivative (41%) it
is apparent that the TES-group is less stable under these con-
ditions and because of this the TES-protected pentynoic acid
was introduced near the end of the synthesis of the alkyne
functionalized scaﬀold. The synthesis of the scaﬀold could be
streamlined by adaptation and expansion of our earlier work
(Scheme 2).10 Starting from 3-bromopropylamine hydrobro-
mide (5), the first step was the introduction of the oNBS pro-
tecting group to aﬀord oNBS-protected bromopropaneamine
(6) in an excellent yield (96%). Next, triamine 7 was prepared
by reaction with 1,3-diaminopropane in DMA, followed by
the protection of the other primary amine of triamine 7
with a trifluoroacetyl (TFA) protection group, using ethyl
trifluoroacetate. Coupling of pentynoic acid to the secondary
amine using BOP aﬀorded triamine 9 in a yield of 67% over
3 steps.
Cyclization of the triamine was achieved by reaction with
dibromide 10, which was easily synthesized following a litera-
ture procedure,11 to give the skeleton of the TAC-scaﬀold (11)
in 67% yield. Treatment with base removed the methylester
and trifluoroacetyl protecting group. This was followed by pro-
tection of the now free amine with an Fmoc-group to give the
desired free carboxylic acid TAC (12) in an 80% yield.
The Fmoc- and oNBS protected scaﬀold (12) was then
loaded on 2-chlorotrityl-chloride resin. The Fmoc-group was
removed by treatment with piperidine, followed by the BOP-
coupling of TIPS-protected pentynoic acid (4a). Next, the oNBS-
group was removed, followed by the coupling of TES-protected
pentynoic acid (4b). Cleavage from the resin with HFIP
resulted in the final protected trialkyne scaﬀold (13) in a good
overall yield (76% over 6 steps).
Peptide synthesis
Cyclic peptides were synthesized using the method that we pre-
viously described (Fig. 3).8 This method was inspired by the
work of Timmerman et al.12 in which terminal cysteine resi-
dues were alkylated with benzylic dibromide derivative to
cyclize the peptide. In our approach the dibromide was also
Fig. 2 The CD4-binding site of HIV-gp120 (gray) in complex with CD4
(blue).7 Peptides corresponding to the parts of the protein that are
responsible for binding (yellow, green and red) can be mounted onto a
molecular scaﬀold to create a mimic of the interaction sites.
Scheme 1 Synthesis of silyl-protected pentynoic acid derivatives.
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outfitted with a benzylic azide (13) for the attachment to the
scaﬀold. To investigate the influence of peptide cyclization,
linear peptides were also prepared. For the synthesis of the
linear peptides only one cysteine was present in the peptide.
This cysteine residue was alkylated with an azide-containing
mono-bromide (14). Using this method we synthesized pep-
tides involved in the binding of gp120 to the CD4
receptor (Fig. 3). Due to a poor solubility of peptide 17 it was
not acetylated on the N-terminus to improve its solubility.
Therefore, the corresponding linear peptide 20 was also not
acetylated.
Sequential ligation
Cyclic and linear peptides were ligated onto the scaﬀold using
a similar protocol as previously described8 with some improve-
ments of the route. It appeared that the CuAAC reactions did
not require microwave irradiation for completion. This also
prevented the partial cleavage of the TES-group during the first
ligation step. As a result the TES-deprotection step could be
combined with the CuAAC step to ligate the first peptide on
the scaﬀold (Scheme 3). After purification the TES-deprotected
scaﬀolds (22a–d), with the first cyclic peptide attached, were
obtained in good yields (45–67%).
Subsequently, the second cyclic peptide was ligated onto
the scaﬀold with very good yields (23a–d, 63–84%). Removal of
the TIPS-protecting group with TBAF, gave the free alkyne
scaﬀolds (24a–d, 43–87%), to which the last cyclic peptide was
ligated, which aﬀorded the epitope mimics 25a–d in 36–59%
yields.
In total four epitope mimics were synthesized (Fig. 4).
Three (25a–c) were based on cyclic peptides 16–18. In these
three mimics the order of introducing the peptides was varied
as to evaluate the influence of the relative positions of the pep-
tides. In addition, one more mimic (20d) was synthesized con-
taining the linear peptides 19–21 to evaluate the relative
influence of cyclic peptides and linear peptides on the biologi-
cal activity of the mimics.
Biological activity
The three cyclic mimics (25a–c) were tested on their ability to
competitively inhibit the interaction between CD4 and gp120
in an ELISA assay (Fig. 5). The procedure for this assay was
described in our previous work.3a,b This experiment showed
little diﬀerence between the three mimics. All three showed
good inhibition with IC50 values between 41 and 57 μM
(Table 1).
Scheme 2 Synthesis of the protected tri-alkyne scaﬀold. The synthesis is an adaptation and expansion on the most recent synthesis of the ortho-
gonally protected triamine TAC-scaﬀold.10
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Fig. 3 (A) General scheme for the synthesis of azide-bearing cyclic peptide.8 (B) General scheme for the synthesis of azide-bearing linear peptides.
(C) The three segments (yellow, green and red) of the HIV gp120 protein (gray) that are responsible for binding to CD4 (blue) are shown.7 Their
amino acid residues and N → C direction are noted. (D) The cyclic (left) and linear (right) peptides that were synthesized according to (A) and (B)
were based on the sequences of the HIV gp120 epitope (as shown in C).
Scheme 3 Sequential introduction of azide functionalized peptides onto the orthogonally protected tri-alkyne scaﬀold.
Fig. 4 Synthesized protein mimics 25a–d. Mimics 25a–c have the same three peptides attached, but the relative positioning of the peptides is
diﬀerent. Mimic 25d has the same relative positioning as mimic 25a but has linear peptides instead of cyclic.
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This suggests that the relative positioning of the peptides in
the three gp120 protein mimics with respect to the CD4-recep-
tor is similar. Possibly, the flexibility of the TAC-scaﬀold is at
least partly responsible for a similar orientation of the three
loops.
The epitope mimic based on linear peptides (25d) was also
able to inhibit the binding of gp120 to CD4. However, the
linear construct inhibits the binding to a lesser extent, with an
about two-fold higher IC50. This suggests that the use of cyclic
of the peptides is beneficial for obtaining better protein
mimics. This might be explained by an improved resemblance
of cyclic peptides to the corresponding peptide segments,
which are present in loop-like segments in the context of a
protein. If more generally true this will improve mimicry possi-
bilities of a protein binding site and therefore the development
of reliable protein mimics.
To investigate the proteolytic stability of the constructs,
compounds 25a and 25d were incubated with human serum
(Fig. 6). Not entirely unexpected, compound 25a, consisting of
scaﬀolded cyclic peptides, proved to be very stable and had
hardly degraded after 24 hours, while compound 25d, consist-
ing of scaﬀolded linear peptides, started to degrade already
after 1 h and after 24 h only 25% remained intact. This
result further underlines the importance of the use of cyclic
peptides over linear peptides in order to obtain optimal
protein mimics.
Conclusions
In this paper we have described an eﬃcient and robust conver-
gent route for the synthesis of protein mimics of discontinu-
ous epitopes consisting of three loops on a suitable scaﬀold.
The challenge here was the molecular construction of
gp120 mimics encompassing the CD4 binding site. The result-
ing molecular constructs were adequate and capable of com-
peting with gp120 for binding to the CD4 receptor. The relative
position of the peptide loops had little influence on the ability
to bind the CD4-receptor.
To investigate whether cyclic peptides have an advantage
over linear we also synthesized a protein mimic based on linear
peptides. This mimic was able to compete with gp120 for
binding with CD4, but to a lesser extent than the cyclic peptide-
based mimics. This shows the beneficial eﬀect of the use of
cyclic peptides on the bio-activity of the mimic and the impor-
tance of mimicking the conformation of the protein parts as
closely as possible to obtain the best achievable protein mimic.
The benefits of the use of cyclic peptides are underlined by the
increased proteolytic stability of the constructs based on cyclic
peptides as opposed to the constructs based on linear peptides.
We expect that this approach for the molecular construction
of protein mimics is applicable to many other proteins in
which several diﬀerent peptide loops are crucial for their bio-
logical activity.
Experimental section
General information
Chemicals were obtained from commercial sources and used
without further purification, unless stated otherwise. Peptide
Fig. 5 Percentage of inhibition of binding of gp120 to CD4 by of the
three discontinuous epitope mimics based on cyclic peptides (25a–c)
and one based on linear peptides (25d) at diﬀerent concentrations.
Table 1 IC50 values for protein mimics 25a–d
IC50 (μM) Log IC50 with standard error
25a 43.7 1.64 ± 0.040
25b 41.3 1.62 ± 0.043
25c 57.3 1.76 ± 0.042
25d 91.1 1.96 ± 0.068
Fig. 6 Serum stability of constructs 25a and 25d.
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grade DiPEA, CH2Cl2, NMP, TFA and HPLC grade solvents were
purchased from Biosolve B.V. (Valkenswaard, The Netherlands).
Fmoc-protected amino acids and BOP were purchased from GL
Biochem Ltd (Shanghai, China). Used amino acids with side
chain protecting groups were as follows: Fmoc-Arg(Pbf ), Fmoc-
Asp(OtBu), Fmoc-Cys(Trt), Fmoc-Gln(Trt), Fmoc-Glu(OtBu),
Fmoc-His(Trt), Fmoc-Thr(tBu) and Fmoc-Trp(Boc). TentaGel S
RAM resin (particle size 90 μm, capacity 0.25 mmol g−1) was
purchased from Rapp Polymere GmbH (Tübingen, Germany).
Solid phase peptide synthesis was performed on a C.S. Bio
Co. peptide synthesizer (model CS336X). Unless stated other-
wise, reactions were performed at room temperature. TLC ana-
lysis was performed on Merck precoated silica gel 60 F-254
plates. Spots were visualized with UV-light, ninhydrin stain
(1.5 g ninhydrin and 3.0 mL acetic acid in 100 mL n-butanol),
potassium permanganate (1.5 g of KMnO4, 10 g K2CO3, and
1.25 mL 10% NaOH in 200 mL water) and/or molybdenum
staining agent (12 g ammonium molydate and 0.5 g
ammonium cerium(IV) sulfate in 250 mL 10% H2SO4). Column
chromatography was performed using Silica-P Flash silica
gel (60 Å, particle size 40–63 μm) from Silicycle (Canada). Lyo-
philization was performed on a Christ Alpha 1–2 apparatus.
1H NMR (400 MHz) and 13C NMR (100 MHz) experiments were
conducted on a 300 MHz Varian G-300 spectrometer. Chemical
shifts are given in ppm (δ) relative to TMS (0.00 ppm)
(1H NMR) or relative to CDCl3 (77 ppm) (
13C NMR).
Analytical HPLC was performed on a Shimadzu-10Avp
(Class VP) system using a Phenomenex Gemini C18 column
(110 Å, 5 μm, 250 × 4.60 mm) at a flow rate of 1 mL min−1. The
used buﬀers were 0.1% trifluoroacetic acid in MeCN/H2O 5 : 95
(buﬀer A) and 0.1% trifluoroacetic acid in MeCN/H2O 95 : 5
(buﬀer B). Runs were performed by a standard protocol: 100%
buﬀer A for 2 min, then a linear gradient of buﬀer B (0–100%
in 48 min) and UV-absorption was measured at 214 and
254 nm. Purification by preparative HPLC was performed on a
Prep LCMS QP8000α HPLC system (Shimadzu) using a Pheno-
menex Gemini C18 column (10 μm, 110 Å, 250 × 21.2 mm)
at a flow rate of 12.5 mL min−1. Runs were performed by a
standard protocol: 100% buﬀer A for 5 min followed by a
linear gradient of buﬀer B (0–100% in 70 min) with the same
buﬀers as were described for analytical HPLC.
ESI-TOF MS spectra were recorded on a microTOF mass
spectrometer (Bruker). Samples were diluted with tuning mix
(1 : 1, v/v) and infused at a speed of 300 µL h−1 using a nebuli-
zer pressure of 5.8 psi, a dry gas flow of 3.0 L min−1, a drying
temperature of 180 °C and a capillary voltage of 5.5 kV. Analyti-
cal LC-MS (electrospray ionization) was preformed on Thermo-
Finnigan LCQ Deca XP Max using same buﬀers and protocol
as described for analytical HPLC. All reported mass values are
monoisotopic.
The microtiterplate reader used in the ELISA assays was a
BioTek μQuant (Beun de Ronde, Abcoude, The Netherlands).
Scaﬀold synthesis
tert-Butyl pent-4-ynoate (2).13 According to literature pro-
cedure, 1,4-pentynoic acid (1, 5.0 g, 51.0 mmol), t-BuOH
(9.7 mL, 101.8 mmol) and DMAP (0.3 g, 2.5 mmol) were dis-
solved in CH2Cl2 (10 mL). The mixture was stirred for 10 min.
A solution of DCC (11.55 g, 56.0 mmol) in CH2Cl2 (10 mL) was
added and the resulting mixture was stirred overnight.
Next the formed precipitate was removed by filtration and
washed with CH2Cl2. The filtrate was washed with 0.5 M HCl
(2 × 100 mL), 1 M NaHCO3 (2 × 100 mL) and dried over
Na2SO4. The mixture was filtered and the solvent was removed
by evaporation. The residue was purified by silica gel column
chromatography (CH2Cl2) to give tert-butyl pent-4-ynoate (2) as
a yellowish oil (6.3 g, 40.8 mmol, 80%). Spectroscopic data was
in agreement with literature data.13
tert-Butyl 5-(triisopropylsilyl)pent-4-ynoate (3a). Compound
2 (1.0 g, 6.5 mmol) was dissolved in anhydrous THF (20 mL)
and cooled to −78 °C with a dry ice and acetone bath. n-BuLi
(2.6 mL, 2.5 M in hexane, 6.5 mmol) was added dropwise and
the reaction mixture was stirred for 10 minutes. Then the dry
ice/acetone bath was replaced with an ice bath (0 °C) and
TIPS-Cl (1.7 mL, 7.8 mmol) was added dropwise. The reaction
mixture was stirred for 3 hours at room temperature, after
which it was quenched with 40 mL saturated aqueous NH4Cl.
THF was removed by evaporation in vacuo and the resulting
aqueous slurry was diluted with H2O (50 mL). The mixture was
extracted with EtOAc (3 × 30 mL) and the combined organic
layers were dried over Na2SO4. After filtration, the solvent
was evaporated. The crude product was purified by silica
gel column chromatography (eluent: 10% Et2O in hexanes)
to give tert-butyl 5-(triethylsilyl)pent-4-ynoate (3a) as a
yellow oil (1.4 g, 4.4 mmol, 68%). Rf = 0.55 (5% EtOAc in
petroleum ether 40–60). 1H NMR (400 MHz, CDCl3): δ = 1.04
(m, 21H, CH(CH3)2), 1.44 (s, 9H, C(CH3)3), 2.44–2.54
(m, 4H, CH2CH2).
13C NMR (100 MHz, CDCl3): δ =
11.2 (C ̲H(CH3)2), 15.9 (C(O)CH2C̲H2), 18.6 (CH(C ̲H3)2), 28.1
(C(C̲H3)3), 35.1 (C(O)C ̲H2) 80.6, 80.8 (C ̲CH3, CC̲Si), 107.1
(C ̲CSi), 171.1 (CvO).
tert-butyl 5-(triethylsilyl)pent-4-ynoate (3b). Compound 2
(1.4 g, 9.3 mmol) was dissolved in anhydrous THF (20 mL) and
cooled to −78 °C with a dry ice and acetone bath. n-BuLi
(3.7 mL, 2.5 M in hexane, 9.3 mmol) was added dropwise and
the reaction mixture was stirred for 10 minutes. Then the dry
ice/acetone bath was replaced with an ice bath (0 °C) and
TES-Cl (1.9 mL, 11.2 mmol) was added dropwise. The reaction
mixture was stirred for 3 hours at room temperature, after
which it was quenched with 40 mL aqueous saturated NH4Cl.
THF was removed by evaporation in vacuo and the resulting
aqueous slurry was diluted with H2O (50 mL). The mixture was
extracted with EtOAc (3 × 30 mL) and the combined organic
layers were dried over Na2SO4. After filtration, the solvent was
evaporated. The crude product was purified by silica gel
column chromatography (eluent: 2% EtOAc in hexanes) to give
tert-butyl 5-(triethylsilyl)pent-4-ynoate (3b) as a yellow oil
(1.8 g, 6.7 mmol, 72%). Rf = 0.54 (5% EtOAc in petroleum ether
40–60). 1H NMR (400 MHz, CDCl3): δ = 0.55 (q, J = 8 Hz, 6H,
CH̲2 ̲–CH3), 0.96 (t, J = 8 Hz, 9H, CH2–CH̲3 ̲) 1.45 (s, 9H, CCH̲3)̲,
2.43–2.53 (m, 4H, CH2–CH2).
13C NMR (100 MHz, CDCl3): δ =
4.4 (C ̲H2–CH3), 7.4 (CH2–C̲H3), 15.9 (C(O)CH2–C̲H2), 28.0
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(CC ̲H3), 35.0 (C(O)C ̲H2) 80.6, 82.2 (C̲CH3, CC̲Si), 106.5 (C̲CSi),
171.1 (CvO).
5-(Triisopropylsilyl)4-pentynoic acid (4a). Compound 3a
(1.3 g, 4.3 mmol) was dissolved in 15% TFA in CH2Cl2 (50 mL)
and the resulting mixture was stirred for 2 hours. The mixture
was then quenched with 1 M ammonium acetate (100 mL) and
extracted with CH2Cl2 (2 × 75 mL). The combined organic
layers were dried over Na2SO4, filtered and evaporated. The
crude product was purified by silica gel column chromato-
graphy (10% Et2O in hexanes). 5-(Triethylsilyl)4-pentynoic acid
(4a) was obtained as a yellow oil (1.1 g, 4.1 mmol, 97%). Rf =
0.33 (30% EtOAc in hexanes). 1H NMR (400 MHz, CDCl3):
δ 1.05 (m, 21H, CH(CH3)2), 2.56–2.64 (m, 4H, CH2–CH2).
13C NMR (100 MHz, CDCl3): δ 11.2 (C ̲H2–CH3), 15.6 (C(O)CH2–
CH2), 18.5 (CH2–C̲H3), 33.7 (C(O)CH2), 81.6 (CC ̲Si), 106.2
(C ̲CSi), 177.3 (CvO).
5-(Triethylsilyl)4-pentynoic acid (4b). Compound 3b (1.8 g,
6.7 mmol) was dissolved in 15% TFA in CH2Cl2 (50 mL) and
the resulting mixture was stirred for 2 hours. The mixture was
then quenched with 1 M ammonium acetate (100 mL) and
extracted with CH2Cl2 (2 × 75 mL). The combined organic
layers were dried over Na2SO4, filtered and evaporated. The
crude product was purified by silica gel column chromato-
graphy (eluent: 10% Et2O in hexanes). 5-(Triethylsilyl)4-pent-
ynoic acid (4b) was obtained as a yellow oil (0.55 g, 2.6 mmol,
39%). Rf = 0.34 (10% EtOAc in hexanes).
1H NMR (400 MHz,
CDCl3): δ = 0.56 (q, J = 8 Hz, 6H, CH̲2 ̲–CH3), 0.97 (t, J = 8 Hz,
9H, CH2–CH̲3 ̲), 2.53–2.63 (m, 4H, CH2–CH2).
13C NMR
(100 MHz, CDCl3): δ = 4.4 (C ̲H2–CH3), 7.4 (CH2–C̲H3), 15.6
(C(O)CH2–CH2), 33.5 (C(O)CH2), 82.9 (CC ̲Si), 105.6 (C ̲CSi),
171.1 (CvO).
N-(3-Bromopropyl)-2-nitrobenzene-sulfonamide (6).14 Accord-
ing to literature procedure,14 3-bromo-propylamine hydro-
bromide (5, 15.0 g, 68.5 mmol) and 2-nitrobenzene-sulfonyl
chloride (18.2 g, 82.2 mmol) were dissolved in CH2Cl2
(180 mL) and cooled to 0 °C. After adding TEA (21.9 mL,
164.4 mmol) the mixture was stirred at room temperature for
3 hours. The mixture was washed with 1 M HCl (50 ml), brine
(50 ml) and H2O (50 mL). The organic phase was dried over
Na2SO4, filtered and the solvent was removed under vacuum to
yield the product as a white solid (21.57 g, 66.7 mmol, 97%).
Spectroscopic data was in agreement with literature data.14
oNBS and TFA protected triamine with pentynoic acid
residue 9. For the synthesis of crude compound 8 a literature
procedure was followed.10
To a cooled solution of 1,3 diaminopropane (25.8 mL
309 mmol) in DMA (200 mL) a solution of sulfonamide
bromide 6 (10.0 g, 30.9 mmol) in DMA (50 mL) was added
dropwise. The resulting mixture was stirred overnight at
room temperature. An aqueous solution of 4 M NaOH (aq,
7.7 mL, 30.9 mmol) was added and the mixture was concen-
trated in vacuo to ca. a third of the volume. DMA (100 mL)
was added and again the mixture was concentrated until a
third of the volume remained. This co-evaporation was
repeated until the collected DMA was not basic anymore due
to remaining diaminopropane (pH indicator paper). After
evaporation of the remaining DMA triamine 7 was obtained
as a yellow oil.
To crude intermediate 7 MeCN (150 mL), H2O (0.7 mL,
38.8 mmol) and CF3CO2Et (18.5 mL, 155.2 mmol) were added.
After overnight stirring under reflux the mixture was concen-
trated in vacuo to aﬀord the crude TFA-protected triamine (8)
as a yellow oil.
Crude compound 8 was dissolved in CH2Cl2 (200 mL). BOP
(14.3 g, 32.3 mmol), 4-pentynoic acid (3.0 g, 30.8 mmol) and
NMM (10.4 mL, 95.5 mmol) were added and the mixture was
stirred overnight. The solvent was evaporated and the residue
was dissolved in EtOAc (100 mL) and washed with 5% NaHCO3
(2 × 100 mL), 1 M of KHSO4 (2 × 100 mL) and brine (100 mL).
The organic layer was dried over Na2SO4 and filtered and the
solvent was removed by evaporation. Silica gel column chromato-
graphy (eluent: EtOAc/hexane; 1/1 until removal of the first
yellow band, then 6/4 until the product started to elute and 7/3
to complete the elution of the product) aﬀorded triamine 9 as
a yellow/orange oil (9.53 g, 19.4 mmol, 63%). Rf = 0.61 (20%
hexanes in EtOAc). 1H NMR (400 MHz, CDCl3): δ 1.67–1.76,
1.83–1.92 (2m, 4H, N–CH2–CH̲2 ̲), 1.96 (s, 1H, CCH), 2.54
(m, 4H, C(O)–CH2–CH2), 3.05–3.18, 3.22–3.34 (2m, 4H, 2 ×
NH–CH̲2 ̲–CH2), 3.38–3.45 (m, 4H, CH2–N–CH2), 5.51, 6.19,
6.74 (3m, 2H, NH), 7.69–7.90, 8.07–8.15 (2m, 4H, Ar–H).
13C NMR (100 MHz, CDCl3): δ = 14.7, 14.9, 31.7, 31.9
(N– –C ̲H2), 26.8, 28.1, 28.5, 29.0 (2 × CH2–C̲H2–CH2),
35.8, 40.8, 41.0, 45.4 (2 × NH–C̲H2–CH2), 37.4, 42.2, 42.8, 45.0
(2 × CH2–N–CH2), 68.9, 69.2, 82.9, 83.1(C–CH), 114.5, 117.4
(CF3), 125.1, 125.5, 130.7, 131.0, 132.6, 132.9, 133.2, 133.4,
133.9 (Ar–C), 148.1 (CNO2), 157.1, 157.5 (CF3–C̲vO), 171.6,
172.5 ((CH2)2NC̲vO). Exact mass calculated [M + H]
+: m/z
493.1369 g mol−1. Mass measured: m/z 493.1344 g mol−1.
Triamine cyclization (11). Dibromide 10 was obtained
according to a literature procedure.11
Triamine 9 (3.0 g, 6.1 mmol), dibromide 10 (2.0 g,
6.1 mmol) and Cs2CO3 (8.0 g, 24.4 mmol) were dissolved in
DMF (500 mL) and the resulting mixture was stirred overnight.
After evaporation of DMF both EtOAc (300 mL) and H2O
(180 mL) were added. The organic layer was washed with an
aqueous solution of 1 M KHSO4 (200 mL) and with brine
(200 mL), dried over Na2SO4 and filtered Concentration
in vacuo aﬀorded the crude product as an orange oil which was
purified using silica gel column chromatography (eluent: 2%
acetone in CH2Cl2). Compound 11 was obtained as a yellow to
orange foam (2.7 g, 4.1 mmol, 67%). Rf = 0.38 (EtOAc/Hexanes,
7 : 3). 1H NMR (400 MHz, CDCl3): δ 1.23–1.45, 1.60–1.70 (2m,
4H, 2 × N–CH2–CH̲2 ̲), 1.92 (m, 1H, CCH), 2.435–2.47 (m, 4H,
C(O)–CH2–CH2), 3.93, 3.95 (2s, 3H, OCH3), 4.38–4.53,
4.63–4.80 (2m, 4H, 2 × Ar–CH2–N), 7.65–8.11 (m, 7H, ArH).
Exact mass calculated [M + H]+: m/z 653.1893 g mol−1. Mass
measured: m/z 653.1879 g mol−1.
Pentynoic acid amidated TAC-scaﬀold 12. Compound 11
(1.7 g, 2.6 mmol) was dissolved in dioxane/MeOH/aq NaOH
(4 M) (15 : 4 : 1, 91 mL, 18.2 mmol) and the resulting mixture
was stirred overnight. 1 M HCl was added until the mixture
was pH neutral (pH indicator paper), after which MeCN
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(50 mL) and H2O (50 mL) were added. The pH was adjusted to
approximately 8 using DiPEA (using a pH electrode) and a
solution of Fmoc-OSu (0.95 g, 2.8 mmol) in MeCN. This was
followed by the dropwise addition of DiPEA to maintain the
pH at 8. The reaction was considered complete when no more
DiPEA was needed to keep the pH above 7.5 for 10 min.
Addition of aqueous solution of HCl (1 M, 30 mL) and H2O
(200 mL) was followed by extraction with EtOAc (2 × 200 mL).
The combined organic layers were washed with brine and
dried over Na2SO4. Evaporation of the solvents gave the crude
compound which was purified using silica gel column chromato-
graphy (gradient from EtOAc/Hexanes/AcOH 8/2/0.1 to 0.1%
AcOH in EtOAc to give the Fmoc-protected TAC-scaﬀold (12)
(1.6 g, 2.1 mmol, 80%) Rf = 0.37 (6% MeOH/CH2Cl2). Exact
mass calculated [M + H]+: m/z 765.2594 g mol−1. Mass
measured: m/z 765.2618 g mol−1.
Orthogonally protected trialkyne TAC-scaﬀold 13. TAC-
scaﬀold 12 (0.3 g, 0.4 mmol) was dissolved in CH2Cl2 (20 mL)
and DiPEA (70 μL, 0.4 mmol) and 2-chlorotrityl chloride resin
(1.0 g, 3.2 mmol) were added. After 5 minutes DiPEA (105 μL,
0.6 mmol) was added and the mixture was stirred overnight.
DiPEA (1 mL) and MeOH (4 mL) were added and the mixture
was stirred for 30 minutes. The resin was transferred to a solid
phase synthesis tube and washed with MeOH (3 × 20 mL) and
Et2O (3 × 20 mL). After drying for 30 minutes, 5 mg of resin
was transferred to a 20 mL volumetric flask and 20% piper-
idine in NMP (2 mL) was added. The flask was shaken for
30 minutes after which MeOH was added until a volume of
20 mL. UV-absorption was measured at 300 nm resulting in a
loading of 0.25 mmol g−1 resin (loading yield of 63%). The
resin was washed with CH2Cl2 (3 × 20 mL), NMP (3 × 20 mL)
and 20% piperidine/NMP (20 mL) was added. The mixture was
bubbled through with N2 for 30 minutes, followed by washing
with NMP (3 × 20 mL) and CH2Cl2 (3 × 20 mL). A positive
Bromophenol Blue-test indicated Fmoc removal.
Next, BOP (0.22 g, 0.5 mmol), CH2Cl2 (20 mL), TIPS-
protected pentynoic acid 4a (0.13 g, 0.5 mmol), DiPEA (1.7 mL,
1.0 mmol) were added respectively. The mixture was bubbled
through with N2 for 2 hours. Then the resin was washed with
CH2Cl2 (3 × 20 mL). A negative Bromophenol Blue-test indi-
cated coupling of the pentynoic acid derivative.
The resin was washed with DMF (3 × 20 ml). DMF (20 mL),
β-mercaptoethanol (175 μL, 2.5 mmol) and DBU (187 μL,
152.24 g mol−1, 1.25 mmol, 1.02 g cm−3, 5 equiv.) were added
subsequently. The mixture was bubbled through with N2 for
15 minutes. The deprotection step was repeated once.
The resin was washed with DMF (3 × 20 mL) and CH2Cl2
(3 × 20 mL). A positive Bromophenol Blue-test indicated oNBS
removal.
Next, BOP (0.22 g, 0.5 mmol), CH2Cl2 (20 ml), TES-
protected pentynoic acid 4b (0.11 g, 0.5 mmol) and DiPEA
(166.8 μL, 1.0 mmol) were added and the mixture was bubbled
through with N2 for 2 hours. The resin was washed with
CH2Cl2 (3 × 20 mL) and a negative Bromophenol Blue-test indi-
cated coupling of the pentynoic acid derivative. The resin was
transferred to a round-bottom flask and 30% HFIP in CH2Cl2
(20 mL) was added. The mixture was allowed to stir for
45 minutes. After filtration and washing of the residue with
CH2Cl2, EtOAc (30 mL) was added to the filtrate. The solvents
were removed by evaporation. Silica gel column chromato-
graphy (6% MeOH in CH2Cl2) aﬀorded scaﬀold 13 as a color-
less oil. The oil was dissolved in t-BuOH/H2O and lyophilized
to obtain a white solid (0.15 g, 0.19 mmol, 76%). Rf = 0.55
(10% MeOH in CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.57
(q, J = 7.9 Hz, 6H, 3 × CH̲2 ̲CH3), 0.97 (t, J = 7.9 Hz, 9H,
3 × CH2CH̲3 ̲), 1.04 (m, 21H, 3 × CH(CH3)2), 1.32–1.60 (m, 4H,
N–CH2–CH̲2 ̲–CH2–N), 1.92 (m, 1H, CCH), 2.44 (m, 4H,
CH̲2 ̲CH̲2 ̲CCH), 2.60–2.78 (m, 8H, 2 × CH̲2 ̲CH̲2 ̲CCSi), 2.81–3.08,
3.40–3.50 (2m, 8H, N–CH̲2 ̲–CH2–CH̲2 ̲–N), 4.59–4.72 (m, 4H,
2 × N–CH2–Ar).
13C NMR (100 MHz, CDCl3): δ = 4.4 (SiCH2),
7.5 (SiCH2C̲H3), 11.2 (SiCH), 14.5, 14.5 (C̲H2CCH), 16.3, 16.4
(C ̲H2CCSi), 18.6 (SiCH(C̲H3)2), 28.0, 28.0, 28.3 (CH2C̲H2CH2),
31.9, 31.9 (C ̲H2CH2CCH), 32.8, 33.1, 33.1 (C̲H2CH2CCSi), 43.5,
45.5, 45.6, 45.7, 46.0, 48.2, 48.3 (NCH2CH2C̲H2N), 52.0, 52.1,
53.8, 53.8 (ArC ̲H2N), 68.8 (CC ̲H), 81.2, 81.3, 82.7, 82.7, 83.1,
83.2 (C ̲CH, CC̲Si), 106.4, 106.4, 107.0, 107.0 (C ̲CSi), 128.8,
130.0, 130.0, 130.1, 130.3, 131.1, 131.2, 131.5, 131.6, 138.2,
140.5 (ArC), 168.9, 170.7, 172.0, 172.5 (CvO). Exact mass
calculated [M + H]+: m/z 788.4854 g mol−1. Mass measured:
m/z 788.4831 g mol−1.
1-(Azidomethyl)-3-(bromomethyl)-benzene (15). 1,3-Bis(bromo-
methyl)-benzene (1.32 g, 5.00 mmol) was dissolved in DMF
(40 ml), followed by the dropwise addition of a suspension of
NaN3 (0.29 g, 4.46 mmol, 0.9 eq.) in DMF (10 ml). The result-
ing mixture was stirred for 3 h and the reaction was monitored
using TLC (10% EtOAc in hexanes). Upon completion of the
reaction, the mixture was concentrated in vacuo, which yielded
a yellow oil that contained NaBr-salt precipitation. The oil was
dissolved in EtOAc and the resulting mixture was filtered. The
filtrate was concentrated in vacuo and purified using silica gel
column chromatography (0.5% EtOAc in hexanes), which
yielded the product as a clear light yellow oil. Despite multiple
purification attempts, 1,3-bis(azidomethyl)-benzene remained
as an impurity. Analysis by 1H-NMR provided a ratio of 70 : 30
for 1-(azidomethyl)-3-(bromomethyl)-benzene (15) and 1,3-bis-
(azidomethyl)-benzene, respectively. Yield: 0.72 g (of which
0.53 g monoazide). Rf (monoazide: 0.63 (10% EtOAc in PE).
1H-NMR (400 MHz, CDCl3): δ = 4.35, 4.36 (s, 2H, CH2N) 4.49
(s, 2H, CH2Br), 7.23–7.40 (m, 4H, Ar–H).
13C-NMR (100 MHz,
CDCl3): δ = 32.97 (CH2Br), 54.43, 54.50 (CH2N3), 127.80,
128.01, 128.10, 128.66, 128.90, 129.31, 129.34, 136.13, 136.15,
138.47 (Ar–C).
Peptide synthesis
Solid phase peptide synthesis. Linear peptides were syn-
thesized on a C.S. Bio Co. peptide synthesizer using Tentagel
S RAM resin (rink amide linker) on a 0.25 mmol scale. Fmoc-
deprotection was performed using 20% piperidine in NMP.
Fmoc-deprotection was monitored by piperidine–benzofulvene
adduct fluorescence using an UV-detector (305 nm). If a sig-
nificant amount of the piperidine–benzofulvene adduct was
detected in the second deprotection step a double coupling of
Paper Organic & Biomolecular Chemistry
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the subsequent amino acid was performed. Amino acids are
coupled using 4 equiv. of amino acid and HBTU as activating
agent with DiPEA as base and NMP as solvent. Capping was
performed using acetic anhydride (12 mL), HOBt (50 mg) and
DiPEA (5.5 ml) in NMP (250 mL). Note: for peptides containing
a Asp-Gly sequence (i.e. 16 and 19) that glycine residue was
coupled as Fmoc-(Dmb)-Gly-OH to prevent aspartimide
formation.
General procedure for the cleavage and deprotection of
the linear peptide from the solid support. The sidechain-
protected linear peptide was cleaved from the resin and de-
protected using a mixture of TFA :H2O : EDT : TIS (90 : 5 : 2.5 : 2.5)
(v/v/v/v), 10 mL per gram resin. The reaction mixture was
stirred for 3 hours after which the mixture was concentrated to
a volume of 2 mL, followed by precipitation of the peptides
from MTBE/hexane (1 : 1 v/v). After centrifugation (3500 rpm,
5 min), the supernatant was decanted and the pellet was re-
suspended in MTBE/hexane (1 : 1 v/v) and centrifuged again. The
pellet was dissolved in t-BuOH/H2O (1 : 1 v/v) and lyophilized.
The purity of the peptides was analyzed by analytical HPLC
and the peptides were characterized with by spectrometry.
Alkylation of cysteine residues.8 Crude peptide was dis-
solved in 20 mM NH4HCO3 (aq)/MeCN (3/1 (v/v)) (80 ml).
Crude 1-azido-3-bromo-xylene (14) or 1-(azidomethyl)-3,5-bis-
(bromomethyl)-benzene (15) was dissolved in MeCN (5 ml)
and the resulting solution was added dropwise to the crude
peptide solution. The resulting mixture was stirred for 3 h and
the reaction was monitored using LC/MS. Upon completion of
the reaction, the mixture was concentrated in vacuo. The
mixture was lyophilized overnight, which yielded the crude
product as a fluﬀy white powder. The crude product was puri-
fied using preparative HPLC.
Sequential ligation
General procedure for first cycloaddition and subsequent
TES-removal 22a–d. Solutions of TAC-scaﬀold 13 (7.9 mg,
10 μmol) in 100 μL DMF, the peptide loop (10 μmol) in 100 μL
DMF, CuSO4·5H2O (3 μmol, 0.75 mg) in 100 μL H2O, NaAsc
(9 μmol, 1.8 mg) in 100 μL H2O and TBTA (1.5 μmol, 0.8 mg) in
100 μL DMF were prepared (if needed the solutions of CuSO4,
NaAsc and TBTA were prepared as 10-fold solution in 1 mL).
The five solutions were combined and DMF (0.9 mL) and H2O
(0.6 mL) were added to obtain a final volume of 2 mL of DMF/
H2O 3/2 (v/v). The resulting mixture was stirred at room temp-
erature for 3 hours and the progress of the reaction was moni-
tored using LC-MS. When the reaction was complete a
solution of AgNO3 (100 μmol, 17.0 mg) in H2O (0.5 mL) was
added and the mixture was stirred at room temperature for
1 hour. The mixture was then diluted to a volume of 5 mL with
MeCN/H2O/TFA (50/50/0.1), followed by the addition of NaCl
(100 μmol, 5.8 mg) in order to remove Ag+ as an AgCl
precipitate. The formed suspension was centrifuged (5 min,
5000 rpm) and the supernatant was purified using preparative
HPLC. The product-containing fractions were pooled and
lyophilized to obtain the TES-deprotected scaﬀold as a
white solid.
General procedure for the conjugation of the second peptide
onto the scaﬀold (23a–d). Solutions of the scaﬀold – contain-
ing one peptide sequence and one free and one protected
alkyne – (5 μmol 1 equiv.) in 200 μL DMF and of the peptide
(5 μmol, 1 equiv.) in 200 μL DMF were prepared. Stock solu-
tions of CuSO4·5H2O (15 μmol, 3 equiv. in 1 mL H2O), NaAsc
(45 μmol, 9 equiv. in 1 mL H2O) and TBTA (15 μmol, 1.5 equiv.
in 1 mL DMF) were prepared. The solutions of the scaﬀold and
the peptide were combined and 100 μL each of the CuSO4, the
NaAsc and TBTA solutions was added. To the resulting mixture
DMF (0.4 mL) and H2O (0.4 mL) were added to obtain a final
volume of 1.5 mL of DMF/H2O 3 : 2 (v/v). The resulting mixture
was stirred at room temperature (usually for 3 h) and the pro-
gress of the reaction was monitored by LC-MS. When the reac-
tion was complete, the mixture was diluted to a volume of
5 mL with MeCN/H2O/TFA (50/50/0.1). The resulting mixture
was centrifuged (5 min, 5000 rpm) and the supernatant was
purified using preparative HPLC. The product-containing frac-
tions were pooled and lyophilized to obtain the TAC-scaﬀold
with as a white solid.
General procedure for the removal of the TIPS-protecting
group (24a–d). The TIPS-protected scaﬀold (5 μmol) was dis-
solved in DMF (1 mL) and a solution of TBAF·3H2O (50 μmol,
10 equiv.). The resulting mixture was stirred at room tempera-
ture and the progress was monitored by LC-MS. When the reac-
tion was complete (usually after stirring overnight), the
mixture was diluted to a volume of 5 mL with MeCN/H2O/TFA
(50/50/0.1). The resulting mixture was centrifuged (5 min,
5000 rpm) and the supernatant was purified using preparative
HPLC. The product-containing fractions were pooled and lyo-
philized to obtain the product as a white solid.
General procedure for the conjugation of the third peptide
onto the scaﬀold (25a–e). Solutions of the scaﬀold – contain-
ing two peptides and one free alkyne – (5 μmol 1 equiv.) in
200 μL DMF and of the peptide (5 μmol, 1 equiv.) in 200 μL
DMF were prepared. Stock solutions of CuSO4·5H2O (15 μmol,
3 equiv. in 1 mL H2O), NaAsc (45 μmol, 9 equiv. in 1 mL H2O)
and TBTA (7.5 μmol, 1.5 equiv. in 1 mL DMF) were prepared.
The solutions of the scaﬀold and the peptide were combined
and 100 μL each of the CuSO4, the NaAsc and TBTA solutions
was added. To the resulting mixture DMF (0.4 mL) and H2O
(0.4 mL) were added to obtain a final volume of 1.5 mL of
DMF/H2O 3 : 2 (v/v). The resulting mixture was stirred at room
temperature (usually for 3 h) and the progress of the reaction
was monitored by LC-MS. When the reaction was complete,
the mixture was diluted to a volume of 5 mL with MeCN/H2O/
TFA (50/50/0.1). The resulting mixture was centrifuged (5 min,
5000 rpm) and the supernatant was purified using preparative
HPLC. The product-containing fractions were pooled and lyo-
philized to obtain the product as a white solid.
HIV-1 gp120 capture ELISA
Recombinant HIV-1IIIB gp120 protein (referred to as
rgp120 hereafter unless otherwise noted) capture ELISA was
performed according to the manufacturer’s instructions
(ImmunoDiagnostics, Inc., Woburn, MA). A solution of the test
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compound, diluted in sample buﬀer (50 μL 0,1% BSA in PBS)
and 2% DMSO, was added to the CD4-coated plate, which was
immediately followed by the addition of 50 μL 2 μg ml−1
rgp120 (final concentration 1 μg mL−1). After 4 hours incu-
bation at room temperature, the plate was washed with wash
buﬀer (0.1% Tween 20 in PBS) followed by incubation with per-
oxidase-conjugated murine anti-gp120 MAb to detect the
amounts of captured rgp120. Any unbound material was
washed away using wash buﬀer, and the plates were developed
by adding 100 μL per well substrate solution (0.1 mg mL−1
TMB in 0.1 N NaOAc buﬀer pH 5.5, containing 0.003% H2O2).
The reaction was stopped by adding 100 μL 4 N sulfuric acid.
Absorbances (ODs) were read at 450 nm using a microtiterplate
reader. All assays were performed in duplicate and all com-
pounds were tested independently at least three times.
Serum stability assay
4 mg mL−1 construct solutions were prepared in MilliQ. Dupli-
cate samples were prepared with 100 µL peptide solution and
500 µL human serum. The samples were incubated at 37 °C,
and samples were taken at t = 0, 1, 8 and 24 h as follows: to
100 µL serum solution, 200 µL MeOH (containing 0.075 mg mL−1
ethylparaben as an internal standard) was added to precipitate
the proteins. The sample was vortexed briefly and allowed to
stand for 10 min at RT. The samples were then centrifuged at
12 000 rpm for 5 min, and the supernatant was taken and
stored at −20 °C until analysis. Each sample was analyzed
by HPLC, on a C18 column. The peaks were integrated and
normalized to the internal standard.
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